查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1772254

美国分子生物学酵素、试剂和套件市场：市场规模、份额、趋势分析（按产品、应用、最终用途和地区）、细分市场预测（2025-2033）

U.S. Molecular Biology Enzymes, Reagents And Kits Market Size, Share & Trends Analysis Report By Product (Kit and Reagents, Enzymes), By Application (Cloning, NGS, PCR), By End Use, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 137 Pages | 商品交期: 2-10个工作天内

价格

市场规模与趋势：

预计 2024 年美国分子生物学酶、试剂和套件市场价值将达到 59.5 亿美元，预计 2025 年至 2033 年的复合年增长率为 9.65%。

根据美国疾病管制与预防中心（CDC）统计，披衣菌感染、淋病、梅毒等性传染病在过去十年中呈现稳定上升趋势，近年来报告病例已超过250万例。分子技术在研究、诊断和治疗的应用不断扩大。

根据美国癌症协会统计，预计到 2024 年，美国将诊断出超过 200 万例新癌症病例（不包括泌尿系统癌、基底细胞癌和鳞状细胞皮肤癌以及非侵入性原位癌）。这种日益加重的疾病负担预计将维持美国在市场上的领先地位。

2024年11月，加州公共卫生部（CDPH）发现了美国首例经实验室确诊的I型痘苗病毒（mpox）病例。此病例确诊于一名近期曾前往疫区的患者。 PCR检测鑑定出一种非天花正痘病毒，因而确诊为I型痘苗病毒。 I型痘苗病毒的出现凸显了快速精准分子诊断的需求，并促使人们投资于下一代PCR和定序技术。

该市场涵盖广泛的产品，包括聚合酵素、连接酶、核酸酶、缓衝液以及用于PCR、qPCR、RT-PCR、克隆、定序和基因表现分析等过程的专用试剂组。此外，肠病毒也会感染5岁以下儿童，其中约41%的感染儿童需要吸氧治疗。此外，根据美国国家医学图书馆2021年5月发表的一篇论文，美国每年约有40%的人口受到病菌感染的影响。

预计政府以核准和资金形式提供的支持将在预测期内推动市场成长。例如，2022年5月，雅培的Alinity m STI检测试剂盒获得美国食品药物管理局（FDA）核准，该试剂盒可识别和检测性传播感染（STI）。此外，2020年，美国公共卫生研究院（ASPR）的生物医学高级研究与发展管理局（BRI）和美国国立卫生研究院（NIH）的国家过敏和传染病研究所联合主办了抗菌素抗药性诊断挑战赛，Visby Medical的快速PCR检测试剂盒获得了1900万美元的联邦资助。

此外，2022年9月，RedBud Medicine在A轮融资中筹集了1,000万美元。联邦政府的资金也将有助于提升地方和州检测实验室的能力，以满足日益增长的需求。同样，2023年6月，Accelerate Diagnostics接受2400万美元融资，用于加速其Wave平台和新型快速检测的开发。由于感染疾病的多样性和病原体的抗药性，感染疾病的分子诊断检测菜单不能一成不变或肤浅。

此外，美国市场受到美国主要企业的推动，例如 Promega Corporation 和 Thermo Fisher Scientific，它们提供各种用于诊断的经济高效的高品质酵素。这些公司提供的酵素可用于生物感测器、糖尿病仪、照护现场设备以及肝臟、心血管、肾臟和其他疾病的体外诊断。 2024 年 9 月，Promega 推出了一种新的酵素变体，可减少法医学DNA 分析中的卡顿现象，凸显了其聚合酵素套件的创新。同时，受 PCR 系统升级和高通量实验室的引入推动，qPCR 和 RT-PCR套件依然保持强劲。此外，2021 年 2 月，安捷伦科技推出了安捷伦 Dako SARS-CoV-2 IgG酵素结合免疫吸附测定套件。此套件可检测人类血清或血浆中的 SARS-CoV-2 IgG 抗体。

诊断检测中使用的主要试剂包括萤光标籤、清洗缓衝液、特异性抗体、免疫化学检查以及PCR检测的dNTP和引子混合物等必需化学物质。在分子诊断领域，萤光标记的核苷酸和引子被广泛使用，尤其是在雅培、Illumina和罗氏诊断等行业巨头的推动下。

COVID-19 相关试剂的监管核准也推动了市场发展。美国FDA 于 2021 年 3 月向 BioFire 呼吸道检测板 2.1 颁发了 510(k) 许可，使其能够检测包括 COVID-19 在内的多种呼吸道感染疾病。同样，2020 年 4 月，Ortho Clinical Diagnostics 的 VITROS 免疫诊断抗 SARS-CoV-2 总试剂包和校准器获得了紧急使用授权 (EUA)，这些试剂包和校准器可在 VITROS 诊断系统上运行。此类核准使医护人员能够更好地管理和预防 COVID-19，即使在疫情初期出现暂时供不应求的情况下也是如此。这些供不应求最终透过政府干预、供应链恢復和替代产品的推出得到缓解。

目录

第一章 分析方法与范围

第二章执行摘要

3. 分子生物学酶、试剂和套件市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 分子生物学酵素、试剂和套件市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析

第四章分子生物学酵素、试剂和套件市场：按产品进行的估计和趋势分析

  • 各产品市场占有率（2024 年及 2033 年）
  • 细分仪表板
  • 全球分子生物学酵素、试剂和套件市场（按产品）展望
  • 市场规模预测与趋势分析（2021-2033）
    • 套件和试剂
    • 酵素

第五章分子生物学酶、试剂和套件市场：按应用的估计和趋势分析

  • 按应用分類的市场占有率（2024 年和 2033 年）
  • 细分仪表板
  • 全球分子生物学酵素、试剂和套件市场展望（按应用）
  • 市场规模预测与趋势分析（2021-2033）
    • 复製
    • 定序
    • PCR
    • 表观遗传学
    • 基因分型
    • RCA/MDA
    • RNA治疗学
    • 转录组学
    • 蛋白质体学
    • 液态生物检体
    • 其他用途

第六章分子生物学酶、试剂和套件市场：按最终用途的估计和趋势分析

  • 按最终用途分類的市场占有率（2024 年和 2033 年）
  • 细分仪表板
  • 全球分子生物学酶、试剂和套件市场展望（按最终用途）
  • 市场规模预测与趋势分析（2021-2033）
    • 製药和生物技术
    • 学术研究
    • 医院/诊断
    • 其他的

第七章 竞争态势

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 公司热图分析
  • 公司简介
    • Illumina, Inc.
    • Thermo Fisher Scientific, Inc.
    • Agilent Technologies, Inc.
    • QIAGEN
    • Promega Corporation
    • New England Biolabs
    • Merck KGaA
    • F. Hoffmann-La Roche Ltd.
    • Bio-Rad Laboratories, Inc.
    • Takara Bio, Inc.
    • LGC Limited
Product Code: GVR-4-68040-645-5

Market Size & Trends:

The U.S. molecular biology enzymes, reagents and kits market size was estimated at USD 5.95 billion in 2024 and is projected to grow at a CAGR of 9.65% from 2025 to 2033. The market is driven by growing burden of chronic diseases and infectious diseases such as sexually transmitted diseases (STDs) across the U.S. According to the Centers for Disease Control and Prevention (CDC), STDs such as chlamydia, gonorrhea, and syphilis have been increasing steadily over the past decade, with over 2.5 million cases reported in recent years. The expanding application of molecular technologies in research, diagnostics, and therapeutics.

According to the American Cancer Society, over 2 million new cancer cases are projected to be diagnosed in the U.S. in 2024, excluding basal and squamous cell skin cancers and noninvasive carcinoma in situ, except for urinary bladder cases. This rising disease burden is expected to sustain the country's leadership in the market.

In November 2024, the California Department of Public Health (CDPH) confirmed the first case of clade I mpox in the U.S. through laboratory testing. The diagnosis was made in a patient who had recently traveled to an outbreak region. PCR testing identified non-variola orthopoxvirus and confirmed clade I mpox, with further analysis conducted by the CDC. The emergence of clade I mpox underscores the necessity for rapid and precise molecular diagnostics, fostering investment in next-generation PCR and sequencing technologies.

This market encompasses a broad range of products, including polymerases, ligases, nucleases, buffers, and specialized reagent kits designed for processes such as PCR, qPCR, RT-PCR, cloning, sequencing, and gene expression analysis. Furthermore, enterovirus also majorly affects the population with ages less than 5 years, of which around 41% of the infected toddlers require supplemental oxygen. In addition, according to the article published by the National Library of Medicine in May 2021, around 40 % of the U.S. population in the U.S. is affected by H. pylori infection every year.

The presence of government support in the form of approvals and funding is anticipated to fuel the market growth over the forecast period. For instance, in May 2022, Abbot received approval for its Alinity m STI Assay from the U.S. FDA. The test is capable of differentiating and detecting STIs. In addition, in 2020, ASPR's Biomedical Advanced Research and Development Authority and NIH's National Institute of Allergy and Infectious Diseases organized the Antimicrobial Resistance Diagnostic Challenge in which Visby Medical's rapid PCR test won USD 19 million in federal funding.

In addition, in September 2022, Redbud Medicine raised USD 10 million in Series A funding. Federal funding also helps local and state laboratories increase their capacity and allows them to keep up with increasing demand. Similarly, in June 2023, Accelerate Diagnostics, Inc. received USD 24 million to accelerate the development of the Wave platform and novel rapid testing. Molecular diagnostics test menus for infectious diseases cannot afford to be static or superficial due to the diverse nature of infectious diseases and the building resistance of causative agents.

Furthermore, local presence of key players such as Promega Corporation and Thermo Fisher Scientific, which offer cost-effective, high-quality, & a wide range of enzymes to be used in diagnosis, is driving the U.S. market. These companies offer enzymes that can be used in biosensors, diabetes meters, point-of-care devices, and in vitro diagnosis of liver, cardiovascular, renal, and other disorders. Promega introduced a novel enzyme variant in September 2024 that cuts stutter in forensic DNA analysis, highlighting innovation in polymerase kits. Meanwhile, qPCR and RT-PCR kits remain strong, supported by PCR system upgrades and high-throughput lab adoption. In addition, in February 2021, Agilent Technologies Inc. launched the Agilent Dako SARS-CoV-2 IgG enzyme-linked immunosorbent assay kit. It detects IgG antibodies to SARS-CoV-2 in human blood serum or plasma.

Key reagents used in diagnostic assays include fluorescent tags, washing buffers, specific antibodies, and protein biomarkers for immunochemistry tests, along with essential chemicals like dNTP and primer mixes for PCR testing. In molecular diagnostics, fluorescent-labeled nucleotides and primers are frequently utilized, particularly by industry leaders such as Abbott, Illumina, Inc., and Roche Diagnostics.

Regulatory approvals for COVID-19-related reagents have also fueled the market. The U.S. FDA granted 510(k) clearance for the BioFire Respiratory Panel 2.1 in March 2021, enabling the detection of multiple respiratory infections, including COVID-19. Similarly, in April 2020, Ortho Clinical Diagnostics received an Emergency Use Authorization (EUA) for the VITROS Immunodiagnostic Anti-SARS-CoV-2 Total Reagent Pack and Calibrators, which operate on the VITROS diagnostic systems. Such approvals allow healthcare professionals to better manage and prevent COVID-19, even amidst temporary shortages that occurred early in the pandemic. These shortages were eventually mitigated through governmental interventions, restored supply chains, and the launch of alternative products

U.S. Molecular Biology Enzymes, Reagents And Kits Market Report Segmentation

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. molecular biology enzymes, reagents and kits market report based on product, application, and end use

Product Outlook (Revenue, USD Million, 2021 - 2033)

  • Kits & Reagents
  • PCR Kits
  • qPCR Kits
  • RT-PCR Kits
  • Library Preparation Kits
  • Cloning Kits
  • Purification Kits
  • Gene Editing Kits
  • Other Kits
  • Enzymes
  • Polymerases
    • DNA Polymerases
    • High Fidelity DNA Polymerases
    • Pfu DNA Polymerases
    • Phusion DNA Polymerases
    • Hot Start DNA Polymerases
    • Taq DNA Polymerases High Fidelity
    • Others
    • Thermostable DNA Polymerases
    • Standard Taq DNA Polymerases
    • Tth DNA Polymerases
    • Others
    • Strand-displacing DNA Polymerases
    • Bst DNA Polymerases
    • Phi29 DNA Polymerases
    • Others
    • RNA Polymerases
    • T7 RNA Polymerase
    • SP6 RNA Polymerase
    • T3 RNA Polymerase
    • Other RNA Polymerase
  • Reverse Transcriptase (RTs)
    • M-MLV RT
    • AMV RT
    • Thermostable RT
    • Template Switch
    • TGIRT
    • Induro
    • MarathonRT
  • Ligases
    • DNA Ligases
    • T4 DNA Ligases
    • E coli DNA Ligase
    • Taq DNA Ligase
    • Others
    • RNA Ligases
  • Nucleases
    • DNase I
    • RNase A, RNase H
    • Nickases
    • Restriction Nucleases
    • TdTs
  • Endonucleases
    • EndoQ
    • AP Nuclease
  • Kinases
  • Phosphatases
  • CRISPR-associated Enzymes
    • Cas9
    • Cas12a (Cpf1)
    • Cas13
  • Specialty Enzymes
  • Others
  • Application Outlook (Revenue, USD Million, 2021 - 2033)
  • Cloning
  • Sequencing
  • PCR
  • Epigenetics
  • Genotyping
  • RCA/MDA
  • RNA Therapeutics
  • Transcriptomics
  • Proteomics
  • Liquid Biopsy
  • Other Applications
  • End Use Outlook (Revenue, USD Million, 2021 - 2033)
  • Pharma & Biotech
    • Research
    • Therapeutics/Production
  • Academic & Research
  • Hospital & Diagnostics
  • Others

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Application
    • 1.2.3. End Use
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline.
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product Outlook
    • 2.2.2. Application Outlook
    • 2.2.3. End Use Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Molecular Biology Enzymes, Reagents And Kits Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
    • 3.2.2. Market restraint analysis
  • 3.3. Molecular Biology Enzymes, Reagents And Kits Market Analysis Tools
    • 3.3.1. Industry Analysis Porter's
    • 3.3.2. PESTEL Analysis

Chapter 4. Molecular Biology Enzymes, Reagents And Kits Market: Product Estimates & Trend Analysis

  • 4.1. Product Market Share, 2024 & 2033
  • 4.2. Segment Dashboard
  • 4.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Product Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 4.4.1. Kits & Reagents
      • 4.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.2. PCR Kits
        • 4.4.1.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.3. qPCR Kits
        • 4.4.1.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.4. RT-PCR Kits
        • 4.4.1.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.5. Library Preparation Kits
        • 4.4.1.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.6. Cloning Kits
        • 4.4.1.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.7. Purification Kits
        • 4.4.1.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.8. Gene Editing Kits
        • 4.4.1.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.1.9. Other Kits
        • 4.4.1.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 4.4.2. Enzymes
      • 4.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.2. Polymerases
        • 4.4.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.2. DNA Polymerases
          • 4.4.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.2. High Fidelity DNA Polymerases
            • 4.4.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.2. Pfu DNA Polymerases
      • 4.4.2.2.2.2.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.3. Phusion DNA Polymerases
            • 4.4.2.2.2.2.4. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.5. Hot Start DNA Polymerases
            • 4.4.2.2.2.2.6. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.2.7. Taq DNA Polymerases High Fidelity
          • 4.4.2.2.2.3. Thermostable DNA Polymerases
            • 4.4.2.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.2. Standard Taq DNA Polymerases
      • 4.4.2.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.3. Tth DNA Polymerases
      • 4.4.2.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
            • 4.4.2.2.2.3.4. Others
      • 4.4.2.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.4. Strand-displacing DNA Polymerases
          • 4.4.2.2.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.6. Bst DNA Polymerases
            • 4.4.2.2.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.7. Phi29 DNA Polymerases
            • 4.4.2.2.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.2.8. Others
            • 4.4.2.2.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.2.3. RNA Polymerases
          • 4.4.2.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.2. T7 RNA Polymerase
            • 4.4.2.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.3. SP6 RNA Polymerase
            • 4.4.2.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.4. T3 RNA Polymerase
            • 4.4.2.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.2.3.5. Other RNA Polymerase
            • 4.4.2.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.3. Reverse Transcriptase (RTs)
        • 4.4.2.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.2. M-MLV RT
          • 4.4.2.3.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.3. AMV RT
          • 4.4.2.3.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.4. Thermostable RT
          • 4.4.2.3.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.5. Template Switch
          • 4.4.2.3.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.6. TGIRT
          • 4.4.2.3.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.7. Induro
          • 4.4.2.3.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.3.8. MarathonRT
          • 4.4.2.3.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.4. Ligases
        • 4.4.2.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.2. DNA Ligases
          • 4.4.2.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.2. T4 DNA Ligases
          • 4.4.2.4.2.3. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.4. E coli DNA Ligase
          • 4.4.2.4.2.5. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.6. Taq DNA Ligase
          • 4.4.2.4.2.7. market estimates and forecasts 2021 to 2033 (USD Million)
          • 4.4.2.4.2.8. Others
          • 4.4.2.4.2.9. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.4.3. RNA Ligases
          • 4.4.2.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.5. Nucleases
        • 4.4.2.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.2. DNase I
          • 4.4.2.5.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.3. RNase A, RNase H
          • 4.4.2.5.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.4. Nickases
          • 4.4.2.5.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.5. Restriction Nucleases
          • 4.4.2.5.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.5.6. TdTs
          • 4.4.2.5.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.6. Endonucleases
        • 4.4.2.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.2. EndoQ
          • 4.4.2.6.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.6.3. AP Nuclease
          • 4.4.2.6.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.7. Kinases
        • 4.4.2.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.8. Phosphatases
        • 4.4.2.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.9. CRISPR-associated Enzymes
        • 4.4.2.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.2. Cas9
          • 4.4.2.9.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.3. Cas12a (Cpf1)
          • 4.4.2.9.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
        • 4.4.2.9.4. Cas13
          • 4.4.2.9.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.10. Specialty Enzymes
        • 4.4.2.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
      • 4.4.2.11. Others
        • 4.4.2.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Molecular Biology Enzymes, Reagents And Kits Market: Application Estimates & Trend Analysis

  • 5.1. Application Market Share, 2024 & 2033
  • 5.2. Segment Dashboard
  • 5.3. Global Molecular Biology Enzymes, Reagents And Kits Market by Application Outlook
  • 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 5.4.1. Cloning
      • 5.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.2. Sequencing
      • 5.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.3. PCR
      • 5.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.4. Epigenetics
      • 5.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.5. Genotyping
      • 5.4.5.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.6. RCA/MDA
      • 5.4.6.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.7. RNA Therapeutics
      • 5.4.7.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.8. Transcriptomics
      • 5.4.8.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.9. Proteomics
      • 5.4.9.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.10. Liquid Biopsy
      • 5.4.10.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 5.4.11. Other Applications
      • 5.4.11.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Molecular Biology Enzymes, Reagents And Kits Market: End use Estimates & Trend Analysis

  • 6.1. End use Market Share, 2024 & 2033
  • 6.2. Segment Dashboard
  • 6.3. Global Molecular Biology Enzymes, Reagents And Kits Market by End use Outlook
  • 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
    • 6.4.1. Pharma & Biotech
      • 6.4.1.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.2. Academic & Research
      • 6.4.2.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.3. Hospital & Diagnostics
      • 6.4.3.1. market estimates and forecasts 2021 to 2033 (USD Million)
    • 6.4.4. Other
      • 6.4.4.1. market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. Illumina, Inc.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/Strategic Initiatives
    • 7.4.2. Thermo Fisher Scientific, Inc.
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/Strategic Initiatives
    • 7.4.3. Agilent Technologies, Inc.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/Strategic Initiatives
    • 7.4.4. QIAGEN
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/Strategic Initiatives
    • 7.4.5. Promega Corporation
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/Strategic Initiatives
    • 7.4.6. New England Biolabs
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/Strategic Initiatives
    • 7.4.7. Merck KGaA
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/Strategic Initiatives
    • 7.4.8. F. Hoffmann-La Roche Ltd.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/Strategic Initiatives
    • 7.4.9. Bio-Rad Laboratories, Inc.
      • 7.4.9.1. Participant's Overview
      • 7.4.9.2. Financial Performance
      • 7.4.9.3. Product Benchmarking
      • 7.4.9.4. Recent Developments/Strategic Initiatives
    • 7.4.10. Takara Bio, Inc.
      • 7.4.10.1. Participant's Overview
      • 7.4.10.2. Financial Performance
      • 7.4.10.3. Product Benchmarking
      • 7.4.10.4. Recent Developments/Strategic Initiatives
    • 7.4.11. LGC Limited
      • 7.4.11.1. Participant's Overview
      • 7.4.11.2. Financial Performance
      • 7.4.11.3. Product Benchmarking
      • 7.4.11.4. Recent Developments/Strategic Initiatives

List of Tables

  • Table 1 List of key distributors and channel partners
  • Table 2 List of key emerging companies'/technology disruptors/innovators
  • Table 3 U.S. Molecular biology enzymes, reagents and kits Market, By Product, 2021 - 2033 (USD Million)
  • Table 4 U.S. Molecular biology enzymes, reagents and kits Market, By Application, 2021 - 2033 (USD Million)
  • Table 5 U.S. Molecular biology enzymes, reagents and kits Market, By End Use, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information procurement
  • Fig. 3 Primary research
  • Fig. 4 Value-chain-based sizing & forecasting
  • Fig. 5 QFD modelling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Market outlook
  • Fig. 9 Segment snapshot-1
  • Fig. 10 Segment snapshot-2
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Market trends & outlook
  • Fig. 13 Porter's five force analysis
  • Fig. 14 PESTEL analysis
  • Fig. 15 U.S. molecular biology enzymes, reagents and kits market: Product outlook key takeaways
  • Fig. 16 U.S. molecular biology enzymes, reagents and kits market: Product movement analysis
  • Fig. 17 Kits & Reagents Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 18 PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 19 qPCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 20 RT-PCR Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 21 Library Preparation Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 22 Cloning Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 23 Purification Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 24 Gene Editing Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 25 Other Kits Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 26 Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 27 Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 28 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 29 High Fidelity DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 30 Pfu DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 31 Phusion DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 32 Hot Start DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 33 Taq DNA Polymerases High Fidelity Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 34 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 35 Thermostable DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 36 Standard Taq DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 37 Tth DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 38 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 39 Strand-displacing DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 40 Bst DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 41 Phi29 DNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 42 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 43 RNA Polymerases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 44 T7 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 45 SP6 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 46 T3 RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 47 Other RNA Polymerase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 48 Reverse Transcriptase (RTs) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 49 M-MLV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 50 AMV RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 51 Thermostable RT Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 52 Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 53 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 54 T4 DNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 55 E. coli DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 56 Taq DNA Ligase Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 57 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 58 RNA Ligases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 59 Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 60 DNase I Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 61 RNase A, RNase H Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 62 Nickases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 63 Restriction Nucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 64 TdTs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 65 Endonucleases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 66 EndoQ Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 67 AP Nuclease Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 68 Kinases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 69 Phosphatases Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 70 CRISPR-associated Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 71 Cas9 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 72 Cas12a (Cpf1) Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 73 Cas13 Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 74 Specialty Enzymes Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 75 Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 76 U.S. molecular biology enzymes, reagents and kits market: Application outlook key takeaways
  • Fig. 77 U.S. molecular biology enzymes, reagents and kits market: Application movement analysis
  • Fig. 78 Cloning - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 79 Sequencing - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 80 PCR - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 81 Epigenetics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 82 Genotyping - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 83 RCA/MDA - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 84 RNA Therapeutics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 85 Transcriptomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 86 Proteomics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 87 Liquid Biopsy - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 88 Other Applications - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 89 U.S. molecular biology enzymes, reagents and kits market: End Use outlook key takeaways
  • Fig. 90 U.S. molecular biology enzymes, reagents and kits market: End Use movement analysis
  • Fig. 91 Pharma & Biotech - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 92 Academic & Research - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 93 Hospital & Diagnostics - Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • Fig. 94 Others - Market Estimates and Forecasts, 2021 - 2033 (USD Million)